Infections, Respiratory Tract
Conditions
Keywords
Chronic cough, Haemophilus influenzae
Brief summary
The purpose of this study is to investigate the role of Haemophilus influenzae and other bacteria in causing chronic cough, through a direct comparison of chronic cough cases and healthy controls recruited from paediatric respiratory clinics in the United Kingdom.
Interventions
PROCEDURECough swab
Samples will be tested to determine and characterise the bacteria that may be associated with chronic cough.
PROCEDUREOropharyngeal swab
Samples will be tested to determine and characterise the bacteria that may be associated with chronic cough.
PROCEDURENasopharyngeal swabs
Samples will be tested to determine and characterise the bacteria and viruses that may be associated with chronic cough.
PROCEDUREBlood sample
Samples will be tested to determine and characterise the immunological markers that may be associated with chronic cough.
PROCEDUREBronchoscopy/ bronchoalveolar lavage samples
Samples will be tested to determine and characterise the bacteria, viruses and immunological markers that may be associated with chronic cough.
OTHERData collection
Questionnaire completion.
Sponsors
GlaxoSmithKline
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
6 Months to 72 Months
Healthy volunteers
No
Inclusion criteria
* Subjects who the investigator believes that parent(s)/ legally acceptable representative can and will comply with the requirements of the protocol. * A male or female child between, and including, six to 72 months of age at the time of enrolment. * Written informed consent obtained from the parent(s)/ legally acceptable representative of the subject. * No antibiotic therapy within four weeks prior to the visit. * No cystic fibrosis or known major immunodeficiency such as agammaglobulinaemia, T cell deficiency or Human Immunodeficiency Virus / Acquired Immune Deficiency Syndrome. * No documented evidence or suspicion of gastroesophageal reflux disease. * No evidence of an upper viral respiratory infection four weeks prior to the visit. In addition, all subjects regarded as 'cases' must satisfy all the following criteria at study entry: * Persistent cough greater than eight weeks. * No response to five-day prednisolone treatment. * Chest X-ray showing no evidence of a lobar pneumonia or gross structural abnormality. In addition, all subjects regarded as 'controls' must satisfy the following criteria at study entry: * No respiratory symptoms four weeks prior to the visit. * No documented evidence or suspicion of lung disease upon physical examination.
Exclusion criteria
* Concurrently participating in another study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product. * Use of any investigational or non-registered product within 30 days prior to study procedures, or planned use during the study period. * Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination. * Child in care.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Occurrence of Haemophilus influenzae, in the absence of co-infection with other bacteria, in the lower airways of cases and controls | 12-15 months from study initiation |
Secondary
| Measure | Time frame |
|---|---|
| Occurrence of Streptococcus pneumoniae in the lower airways of cases and controls | 12-15 months from study initiation |
| Occurrence of Haemophilus influenzae in cough swabs and nasopharynx/ oropharynx of cases and controls | 12-15 months from study initiation |
| Occurrence of Haemophilus influenzae in the lower airways and/or nasopharynx/ oropharynx of cases and controls | 12-15 months from study initiation |
| Bacterial load of Haemophilus influenzae in the lower airways and nasopharynx/ oropharynx of cases and controls | 12-15 months from study initiation |
| Occurrence of Haemophilus haemolyticus in the lower airways and nasopharynx/ oropharynx of cases and controls | 12-15 months from study initiation |
| Antimicrobial resistance of Haemophilus influenzae in lower airways | 12-15 months from study initiation |
| Occurrence of viral pathogens in the lower airways and nasopharynx of cases and controls | 12-15 months from study initiation |
| Occurrence of Moraxella catarrhalis in the lower airways of cases and controls | 12-15 months from study initiation |
| Occurrence of other bacterial pathogens in the lower airways of cases and controls | 12-15 months from study initiation |
| Occurrence of Haemophilus influenzae, regardless of co-infection with other bacteria, in the lower airways of cases and controls | 12-15 months from study initiation |
| Occurrence of Moraxella catarrhalis in cough swabs and nasopharynx/ oropharynx of cases and controls | 12-15 months from study initiation |
| Occurrence of Streptococcus pneumoniae in the lower airways and/or nasopharynx/ oropharynx of cases and controls | 12-15 months from study initiation |
| Occurrence of other bacterial pathogens in the lower airways and/or nasopharynx/ oropharynx of cases and controls | 12-15 months from study initiation |
| Bacterial load of Streptococcus pneumoniae in the lower airways and nasopharynx/ oropharynx of cases and controls | 12-15 months from study initiation |
| Bacterial load of Moraxella catarrhalis in the lower airways and nasopharynx/ oropharynx of cases and controls | 12-15 months from study initiation |
| Occurrence of serotypes of Haemophilus influenzae in the lower airways and nasopharynx/ oropharynx of cases and controls | 12-15 months from study initiation |
| Occurrence of serotypes of Streptococcus pneumoniae in the lower airways and nasopharynx/ oropharynx of cases and controls | 12-15 months from study initiation |
| Antimicrobial resistance of Streptococcus pneumoniae in lower airways | 12-15 months from study initiation |
| Antimicrobial resistance of Moraxella catarrhalis in lower airways | 12-15 months from study initiation |
| Occurrence of Streptococcus pneumoniae in cough swabs and nasopharynx/ oropharynx of cases and controls | 12-15 months from study initiation |
Countries
United Kingdom
Outcome results
None listed